{
  "docId": "019de071-dd7f-730a-8977-e46a36e30dcf",
  "docSlug": "abc22aebd2d55a5159142df321cabcee",
  "documentTitle": "Bionomics | IPO Presentation Deck | 38 slides",
  "authorId": "bionomics",
  "authorName": "Bionomics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2021-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7391304,
  "pageNumber": 35,
  "pageCount": 38,
  "prevPage": 34,
  "nextPage": 36,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The slide uses a mix of bullet points and a callout box for the conclusion/explanation of the primary endpoint failure.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-dd7f-730a-8977-e46a36e30dcf/35",
  "deckHref": "/decks/019de071-dd7f-730a-8977-e46a36e30dcf",
  "deckJsonHref": "/decks/019de071-dd7f-730a-8977-e46a36e30dcf.json",
  "deckAnchorHref": "/decks/019de071-dd7f-730a-8977-e46a36e30dcf#slide-35",
  "components": [
    {
      "bbox": {
        "h": 0.2,
        "w": 0.9,
        "x": 0.05,
        "y": 0.72
      },
      "kind": "callout",
      "text": "Potential reasons why clinically significant effects and trends seen at early time points did not translate into significant primary endpoint on CAPS-5 at 12 Weeks: Inadequate overall blood exposure; Lower compliance with liquid suspension.",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "56e2c0ff-1994-4d31-a67a-12674cb81303",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.9,
        "x": 0.05,
        "y": 0.1
      },
      "kind": "list",
      "text": "No overall effect on primary endpoint of CAPS-5 total severity score at 12 weeks. Australian patients had a greater improvement over placebo than US patients. Evidence of antidepressant effect in high dose treatment group. Trend for anxiolytic effect.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "50f6cea7-25c9-42a1-9ecb-ede3a8a23255",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.05,
        "y": 0.03
      },
      "kind": "title",
      "text": "BNC210 PTSD Trial Overall Conclusions",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d929d970-7c35-427b-8c80-70dd9b4e7a7a",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "2ca451c2-9215-44a0-bfd6-08a6a81d99ed",
      "evidence": "The slide contains a list of bullet points.",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}